Sanara MedTech Q2 EPS $(0.05) Misses $0.02 Estimate, Sales $28.137M Miss $28.950M Estimate
HC Wainwright & Co. Downgrades Sanara MedTech to Neutral, Lowers Price Target to $35
Sanara MedTech (SMTI) Stock Gets Fair Value Bump As Analysts Back Wound Care Growth
Sanara Medtech Ends Previously Announced Services Agreement With The Catalyst Group; Not Obliged To Pay Penalty Over Agreement Termination
Sanara MedTech (SMTI) Q1 2026 Earnings Transcript
How The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays Put
Sanara MedTech: From Cash Burner To Profitable Growth
Sanara MedTech Inc. Q1 2026 Earnings Call Summary
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Transcript: Sanara MedTech Q1 2026 Earnings Conference Call
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Sanara MedTech Sees Q2 Sales $28.500M-$29.500M vs $28.650M Est
Sanara MedTech Affirms FY2026 Sales Guidance of $116.000M-$121.000M vs $117.300M Est
Sanara MedTech Q1 EPS $0.05 Beats $(0.04) Estimate, Sales $27.799M Beat $26.800M Estimate
How Sanara MedTech (SMTI) Is Reframing Its Growth Story Around A Steady US$34 Target
Sanara MedTech (SMTI) Q4 2025 Earnings Transcript
What Makes Sanara Medtech (SMTI) A Compelling Risk-Reward Opportunity?
How The Sanara MedTech (SMTI) Story Is Shifting With New Targets And Growth Assumptions
Lake Street Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $32
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.